Insmed Inc

IM8N

Company Profile

  • Business description

    Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.

  • Contact

    700 US Highway 202/206
    BridgewaterNJ08807
    USA

    T: +1 908 977-9900

    E: [email protected]

    https://www.insmed.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    1,664

Stocks News & Analysis

stocks

This defensive ASX listed REIT offers a 5% yield

Solid outlook underpinned by rent uplifts and development pipeline.
stocks

Chart of the Week: Anthropic’s IPO range sits below our fair value

Our fair value is above the IPO range, but outcomes could differ widely.
stocks

Taking a look at opportunities in gaming shares as the highly anticipated GTA 6 is released

Several gaming shares are trading at a discount to our fair value.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,836.6095.80-1.07%
CAC 408,125.8820.95-0.26%
DAX 4025,682.6953.55-0.21%
Dow JONES (US)50,236.2838.110.08%
FTSE 10010,512.8238.35-0.36%
HKSE22,841.62453.13-1.95%
NASDAQ24,868.01438.131.79%
Nikkei 22559,444.21419.930.71%
NZX 50 Index14,247.2517.04-0.12%
S&P 5007,396.4172.780.99%
S&P/ASX 2008,730.4091.40-1.04%
SSE Composite Index3,577.6210.21-0.28%

Market Movers